Domača stranCGEN • NASDAQ
add
Compugen Ltd
1,64 $
Pred odprtjem:(0,00 %)0,00
1,64 $
Konec trgovanja: 13. jan., 04:55:52 GMT -5 · USD · NASDAQ · Izjava
Prejšnji trg. dan.
1,59 $
Dnevni razpon
1,56 $ - 1,72 $
Letni razpon
1,35 $ - 3,03 $
Tržna kapitalizacija
146,84 mio. USD
Povprečni obseg
486,08 tis.
Razm. P/E
85,55
Dividendna donosnost
-
Primarna borza
NASDAQ
Borzne novice
Finančni podatki
Izkaz poslovnega izida
Prihodek
Čisti dohodek
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Prihodek | 17,13 mio. | — |
Stroški poslovanja | 9,04 mio. | −14,99 % |
Čisti dohodek | 1,28 mio. | 112,95 % |
Čista dobičkovnost prihodkov | 7,45 | — |
Earnings per share | 0,01 | 109,09 % |
EBITDA | 4,62 mio. | 143,92 % |
Efektivna davčna stopnja | 77,92 % | — |
Bilanca stanja
Skupna sredstva
Skupne obveznosti
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Denar. in kratkor. naložbe | 112,71 mio. | 95,99 % |
Skupna sredstva | 123,52 mio. | 82,69 % |
Skupne obveznosti | 63,03 mio. | 338,18 % |
Celoten lastniški kapital | 60,49 mio. | — |
Shares outstanding | 89,54 mio. | — |
Razmerje P/B | 2,34 | — |
Donosnost sredstev | 9,62 % | — |
Donosnost kapitala | 18,01 % | — |
Denarni tok
Neto sprememba denarnih sredstev
| (USD) | sep. 2024info | Sprememba L/L |
|---|---|---|
Čisti dohodek | 1,28 mio. | 112,95 % |
Denar iz dejavnosti | — | — |
Denar iz naložb | — | — |
Denar iz financiranja | — | — |
Neto sprememba denarnih sredstev | — | — |
Prost denarni tok | — | — |
Vizitka
Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors. Wikipedia
Generalni direktor
Datum ustanovitve
10. feb. 1993
Spletno mesto
Zaposleni
68
